🔎 Trials Near Me

Hjem › Ægstockræft › Washington

Ægstockræft kliniske forsøg i Washington

38 studier for Ægstockræft søger deltagere på steder i Washington.

Byer i Washington

Officiel studietekst (engelsk)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • Swedish Cancer Institute-Edmonds, Edmonds
  • Swedish Cancer Institute-Issaquah, Issaquah
  • Providence Regional Cancer System-Lacey, Lacey
  • og 4 flere
RekruttererFase 2
Alle aldre · Alle køn · Opdateret 2. okt. 2026 · NCT05564377

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • University of Washington, Fred Hutchinson Cancer Center, Seattle
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT04585750

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

  • Fred Hutchinson Cancer Center, Seattle
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT04981119

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

  • Seattle Cancer Care Alliance at South Lake Union - G3630, Seattle
RekruttererFase 1/2
Alder 18 og opefter · Kvinder · Opdateret 24. sep. 2026 · NCT04590326

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

  • Virginia Mason Hospital and Medical Center /ID# 277259, Seattle
RekruttererFase 2
Alder 18 og opefter · Kvinder · Opdateret 22. sep. 2026 · NCT07059845

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  • Swedish Cancer Institute - Edmonds, Edmonds
  • Swedish Medical Center, Seattle
  • Fred Hutchinson Cancer Center, Seattle
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07213804

IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
RekruttererFase 2
Alder 18 og opefter · Kvinder · Opdateret 21. sep. 2026 · NCT07495124

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

  • University of Washington Fred Hutchinson, Seattle
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 21. sep. 2026 · NCT05983432

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

  • Providence Sacred Heart Medical Center & Children's Hospital, Spokane
RekruttererFase 3
Alder 18 og opefter · Kvinder · Opdateret 15. sep. 2026 · NCT06915025

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Virginia Mason Medical Center, Seattle
  • Fred Hutchinson Cancer Center, Seattle
RekruttererFase 3
Alder 18 og opefter · Kvinder · Opdateret 15. sep. 2026 · NCT07214779

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

  • Providence Sacred Heart Medical Center, Spokane
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT06303505

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

  • Swedish Cancer Institute, Seattle
RekruttererFase 2
Alder 18 og opefter · Kvinder · Opdateret 14. sep. 2026 · NCT06787612

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Madigan Army Medical Center, Tacoma
RekruttererFrivillige med god helbredstilstand velkomne
Alder 45 til 75 · Alle køn · Opdateret 2. sep. 2026 · NCT06995898

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

  • Providence Sacred Heart Medical Center & Children's Hospital, Spokane
RekruttererFase 3
Alder 18 og opefter · Kvinder · Opdateret 26. aug. 2026 · NCT05281471

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

  • Providence Regional Cancer System-Aberdeen, Aberdeen
  • PeaceHealth Saint Joseph Medical Center, Bellingham
  • Providence Regional Cancer System-Centralia, Centralia
  • og 19 flere
Rekrutterer
Alder 35 til 50 · Kvinder · Opdateret 7. aug. 2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  • Providence Regional Cancer System-Aberdeen, Aberdeen
  • PeaceHealth Saint Joseph Medical Center, Bellingham
  • Providence Regional Cancer System-Centralia, Centralia
  • og 20 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 7. aug. 2026 · NCT06580314

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

  • Fred Hutchinson Cancer Center, Seattle
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 5. aug. 2026 · NCT07444814

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  • Wenatchee Valley Hospital and Clinics, Wenatchee
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 5. aug. 2026 · NCT06330064

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • Swedish Cancer Institute, Seattle
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT05579366

Clinical Pre-screening Protocol for Ovarian Cancer

  • Swedish Center for Research and Innovation, Seattle
RekruttererObservationsstudie
Alder 18 og opefter · Kvinder · Opdateret 30. jul. 2026 · NCT03877796

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  • University of Washington - Seattle Cancer Care Alliance, Seattle
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 28. jul. 2026 · NCT06161025

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • University of Washington School of Medicine, Seattle
RekruttererFase 2
Alder 8 og opefter · Alle køn · Opdateret 27. jul. 2026 · NCT05503797

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • Northwest Medical Specialities. PLLC, Bonney Lake
  • Swedish Cancer Institute - Edmonds Campus, Edmonds
  • Swedish Cancer Institute Edmonds Campus, Edmonds
  • og 9 flere
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 6. jul. 2026 · NCT04389632

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

  • Fred Hutchinson Cancer Center, Seattle
  • Summit Cancer Centers, Spokane
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 29. jun. 2026 · NCT05377996

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

  • Fred Hutchinson Cancer Center, Seattle
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 23. jun. 2026 · NCT06993844

Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
RekruttererFrivillige med god helbredstilstand velkomne
Alder 18 og opefter · Alle køn · Opdateret 17. jun. 2026 · NCT07282158

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

  • Fred Hutchinson Cancer Center, Seattle
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 12. jun. 2026 · NCT06051695

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

  • USA09-0, Puyallup
  • USA07-0, Spokane
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 22. maj 2026 · NCT06953089

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

  • Fred Hutchinson Cancer Center, Seattle
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 13. maj 2026 · NCT03686124

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 17. apr. 2026 · NCT06295965

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

  • University of Washington, Seattle
Rekrutterer
Alder 25 til 50 · Kvinder · Opdateret 6. apr. 2026 · NCT04294927

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

  • Northwest Medical Specialties, PLLC, Tacoma
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 1. apr. 2026 · NCT05735080

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

  • Fred Hutchinson Cancer Center, Seattle
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 27. mar. 2026 · NCT06395519

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

  • Fred Hutchinson Cancer Center, Seattle
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. feb. 2026 · NCT06778863

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Seattle
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774

Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer

  • The Swedish Hospital, Seattle
RekruttererObservationsstudie
Alder 30 og opefter · Kvinder · Opdateret 16. sep. 2025 · NCT04794322

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.